nach oben

BioDrugs

Erschienen in:

01.05.2002 | Company Profile

CellControl AG

verfasst von: Nils Behnke

Erschienen in: BioDrugs | Ausgabe 3/2002

Einloggen, um Zugang zu erhalten

Abstract

BioDrugs Company Profiles provide brief overviews of emerging and established companies in the biotechnology industry, featuring information on strategies, product development and R&D partnering. CellControl is a biotech company specialising in the fusion of tumour diagnostics and therapeutics, with the goal of achieving breakthroughs for cancer patients.

Wagner U, Kohler S, Reinartz S, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 2001 May; 7(5): 1154–62PubMed

Grant SC, Kirs MG, Houghton AN, et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999 Jun; 5: 1319–23PubMed

Foon KA, Bhattacharya-Chatterjee M. Are solid tumor anti-idiotype vaccines ready for prime time? Clin Cancer Res 2001 May; 7(5): 1112–5PubMed

Titel: CellControl AG
verfasst von: Nils Behnke
Publikationsdatum: 01.05.2002
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 3/2002
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.2165/00063030-200216030-00005

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

CellControl AG

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2002

Prostate Cancer Vaccine — Northwest Biotherapeutics

Therapeutic Approaches in Multiple Sclerosis

Human Haemoglobin — Hemosol

Gastric Inhibitory Polypeptide Analogues

Waldenström’s Macroglobulinaemia

Profile Summary